JPMorgan Chase & Co. Issues Pessimistic Forecast for Heartflow (NASDAQ:HTFL) Stock Price

Heartflow (NASDAQ:HTFL) had its price target dropped by stock analysts at JPMorgan Chase & Co. from $40.00 to $35.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price points to a potential upside of 34.51% from the company’s previous close.

A number of other research firms have also issued reports on HTFL. Canaccord Genuity Group increased their price target on Heartflow from $40.00 to $43.00 and gave the company a “buy” rating in a research report on Thursday. Wells Fargo & Company cut their target price on shares of Heartflow from $38.00 to $35.00 and set an “overweight” rating on the stock in a research note on Thursday. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Heartflow in a research note on Monday, December 29th. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $37.67.

Heartflow Trading Up 0.5%

Shares of NASDAQ HTFL opened at $26.02 on Thursday. The stock has a market cap of $2.23 billion and a P/E ratio of -14.38. The business’s fifty day simple moving average is $26.86 and its 200-day simple moving average is $30.41. Heartflow has a 12-month low of $20.13 and a 12-month high of $41.22.

Insider Buying and Selling

In other news, Director Julie A. Cullivan sold 9,122 shares of the company’s stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $25.00, for a total transaction of $228,050.00. Following the completion of the sale, the director owned 27,291 shares in the company, valued at $682,275. This represents a 25.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Campbell Rogers sold 65,153 shares of the stock in a transaction that occurred on Thursday, February 12th. The stock was sold at an average price of $24.49, for a total value of $1,595,596.97. Following the transaction, the insider directly owned 76,034 shares of the company’s stock, valued at approximately $1,862,072.66. This trade represents a 46.15% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 2,127,399 shares of company stock worth $59,295,771.

Institutional Trading of Heartflow

Hedge funds and other institutional investors have recently bought and sold shares of the company. Wellington Management Group LLP increased its stake in shares of Heartflow by 20.8% during the 4th quarter. Wellington Management Group LLP now owns 5,894,070 shares of the company’s stock valued at $171,812,000 after acquiring an additional 1,014,006 shares during the last quarter. Baillie Gifford & Co. acquired a new position in shares of Heartflow during the 3rd quarter valued at $101,182,000. Bamco Inc. NY boosted its position in shares of Heartflow by 86.2% in the fourth quarter. Bamco Inc. NY now owns 2,303,877 shares of the company’s stock worth $67,158,000 after buying an additional 1,066,371 shares during the period. Schusterman Interests LLC purchased a new position in Heartflow in the 3rd quarter worth approximately $65,274,000. Finally, Capricorn Investment Group LLC acquired a new stake in Heartflow during the 4th quarter valued at $48,178,000.

Heartflow News Roundup

Here are the key news stories impacting Heartflow this week:

• Positive Sentiment: Q4 revenue beat and strong top‑line growth — HeartFlow reported revenue of $49.13M vs consensus $46.58M, up ~40.5% year‑over‑year, signaling accelerating adoption and top-line momentum. MarketBeat: Q4 results & transcript
• Positive Sentiment: Bullish analyst move — Canaccord raised its price target to $43 and maintained a Buy rating, implying a sizable upside and providing supportive institutional sentiment. Benzinga: Canaccord price target raise
• Neutral Sentiment: Analysts cut targets but stayed positive — JPMorgan lowered its PT from $40 to $35 but kept an Overweight rating, signaling confidence in the business even while trimming valuation assumptions. Benzinga: JPMorgan PT change
• Neutral Sentiment: Wells Fargo also trimmed its PT (from $38 to $35) but maintained an Overweight rating, another sign of cautious optimism. Benzinga: Wells Fargo PT change
• Neutral Sentiment: Independent analysis available — Seeking Alpha published a piece reviewing HeartFlow’s strategy and growth opportunities; useful for investors analyzing the longer‑term thesis. Seeking Alpha: HeartFlow: Getting Into The Flow
• Negative Sentiment: EPS miss and continued losses — HeartFlow reported GAAP EPS of ($0.29) vs consensus ($0.16), missing estimates and underscoring margin pressure and ongoing unprofitability (PE remains negative). MarketBeat: EPS miss / earnings details
• Negative Sentiment: Valuation and trend considerations — Despite the rally, the stock remains below its 50‑day and 200‑day moving averages and carries a wide range of analyst targets, indicating continued volatility and mixed near‑term sentiment. Benzinga: HTFL earnings & estimates

About Heartflow

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.